This presentation from REV Partners contains information about pharmaceutical innovation trends. New drug filings increased slightly from 64 to 65 between fiscal years 2018 and 2019, while new drug approvals declined from 53 to 45. Notable innovation has occurred in specialty diseases like cancer and orphan drugs, which require high prices to generate significant sales. The pharmaceutical industry needs continued innovation to drive long-term revenue growth by pursuing therapies for specialized populations.